[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moderate-to-severe-benign-prostatic-hyperplasia-bph\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moderate-to-severe-benign-prostatic-hyperplasia-bph":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643125",false,"NCT07643220","Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-G721\" and \"G721R\" in Healthy Adult Male Subjects","Inclusion Criteria:\n\n* Healthy male adults aged ≥19 years and \\\u003C55 years at screening.\n* Body weight ≥ 50 kg and body mass index (BMI) between 18 and 30 kg\u002Fm².\n* Clinically healthy based on medical history, physical examination, ECG, and laboratory test results, as determined by the investigator.\n* Willing and able to provide written informed consent.\n* Agrees to use medically acceptable contraception during the required study period.\n\nExclusion Criteria:\n\n* Use of medications known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or other medications that may interfere with the study within 10 days prior to dosing.\n* Participation in another clinical trial involving an investigational product within 6 months prior to the first dose.\n* Whole blood donation within 8 weeks or component blood donation within 2 weeks prior to the first dose.\n* History of gastrointestinal resection that may affect drug absorption.\n* Known hypersensitivity to dutasteride, tamsulosin, or any component of the investigational product.\n* History of psychiatric illness, or any condition considered unsuitable for study participation by the investigator.",true,"MALE","19 Years","54 Years",{"count":20,"type":21},44,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","To evaluate and compare the safety and pharmacokinetic profiles of \"AJU-G721\" (test drug) and \"G721R\" (reference drug) in healthy adult male subjects.",[27],"Moderate-to-severe Benign Prostatic Hyperplasia (BPH)","RECRUITING","2026-06-10",{"date":31,"type":32},"2026-06-12","ACTUAL",{"date":34,"type":21},"2026-06",{"date":36,"type":21},"2026-07",{"name":38,"class":39},"AJU Pharm Co., Ltd.","INDUSTRY",1,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":48,"briefSummary":25,"conditions":49,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":55,"leadSponsor":57,"locationsCount":40},"100643505","NCT07643233","Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions","An Open-Label, Randomized, Fed, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-G721\" and \"G721R\" in Healthy Adult Male Subjects",{"count":47,"type":21},36,[24],[27],"NOT_YET_RECRUITING","2026-06-08",{"date":53,"type":32},"2026-06-11",{"date":36,"type":21},{"date":56,"type":21},"2026-08",{"name":38,"class":39},""]